Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Total Assets
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) holds total assets worth CN¥13.81 Billion CNY (≈ $2.02 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 600267 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Zhejiang Hisun Pharmaceutical Co Ltd - Total Assets Trend (1997–2025)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Zhejiang Hisun Pharmaceutical Co Ltd net assets for net asset value and shareholders' equity analysis.
Zhejiang Hisun Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Hisun Pharmaceutical Co Ltd's total assets of CN¥13.81 Billion consist of 36.0% current assets and 64.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.6% |
| Accounts Receivable | CN¥1.79 Billion | 11.9% |
| Inventory | CN¥1.69 Billion | 11.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥850.48 Million | 5.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1997–2025)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zhejiang Hisun Pharmaceutical Co Ltd (600267) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Hisun Pharmaceutical Co Ltd's current assets represent 36.0% of total assets in 2025, a decrease from 50.2% in 1997.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2025, down from 15.9% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 11.9% of total assets.
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Hisun Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Zhejiang Hisun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 0.97 | 0.74 |
| Quick Ratio | 0.69 | 0.68 | 0.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-14.28 Million | CN¥-182.00 Million | CN¥-2.22 Billion |
Zhejiang Hisun Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Hisun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.55 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.8% |
| Total Assets | CN¥15.05 Billion |
| Market Capitalization | $2.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Hisun Pharmaceutical Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zhejiang Hisun Pharmaceutical Co Ltd's assets decreased by 5.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual total assets of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥15.05 Billion ≈ $2.20 Billion |
-5.77% |
| 2024-12-31 | CN¥15.97 Billion ≈ $2.34 Billion |
-9.32% |
| 2023-12-31 | CN¥17.61 Billion ≈ $2.58 Billion |
-6.20% |
| 2022-12-31 | CN¥18.78 Billion ≈ $2.75 Billion |
-3.08% |
| 2021-12-31 | CN¥19.37 Billion ≈ $2.84 Billion |
-7.12% |
| 2020-12-31 | CN¥20.86 Billion ≈ $3.05 Billion |
-2.82% |
| 2019-12-31 | CN¥21.47 Billion ≈ $3.14 Billion |
-1.78% |
| 2018-12-31 | CN¥21.85 Billion ≈ $3.20 Billion |
+1.00% |
| 2017-12-31 | CN¥21.64 Billion ≈ $3.17 Billion |
+4.23% |
| 2016-12-31 | CN¥20.76 Billion ≈ $3.04 Billion |
+8.26% |
| 2015-12-31 | CN¥19.17 Billion ≈ $2.81 Billion |
+10.85% |
| 2014-12-31 | CN¥17.30 Billion ≈ $2.53 Billion |
+23.81% |
| 2013-12-31 | CN¥13.97 Billion ≈ $2.04 Billion |
+32.20% |
| 2012-12-31 | CN¥10.57 Billion ≈ $1.55 Billion |
+28.41% |
| 2011-12-31 | CN¥8.23 Billion ≈ $1.20 Billion |
+39.00% |
| 2010-12-31 | CN¥5.92 Billion ≈ $866.53 Million |
+13.91% |
| 2009-12-31 | CN¥5.20 Billion ≈ $760.73 Million |
+26.14% |
| 2008-12-31 | CN¥4.12 Billion ≈ $603.08 Million |
+38.04% |
| 2007-12-31 | CN¥2.99 Billion ≈ $436.88 Million |
+6.14% |
| 2006-12-31 | CN¥2.81 Billion ≈ $411.59 Million |
+7.94% |
| 2005-12-31 | CN¥2.61 Billion ≈ $381.32 Million |
+19.55% |
| 2004-12-31 | CN¥2.18 Billion ≈ $318.97 Million |
+16.33% |
| 2003-12-31 | CN¥1.87 Billion ≈ $274.19 Million |
+18.93% |
| 2002-12-31 | CN¥1.58 Billion ≈ $230.55 Million |
+21.29% |
| 2001-12-31 | CN¥1.30 Billion ≈ $190.07 Million |
+7.62% |
| 2000-12-31 | CN¥1.21 Billion ≈ $176.61 Million |
+79.57% |
| 1999-12-31 | CN¥672.12 Million ≈ $98.35 Million |
+38.95% |
| 1998-12-31 | CN¥483.70 Million ≈ $70.78 Million |
+37.06% |
| 1997-12-31 | CN¥352.91 Million ≈ $51.64 Million |
-- |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more